No Data
No Data
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Pliant Therapeutics Analyst Ratings
Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial
Express News | Pliant Therapeutics Inc: Pln-101095 Was Generally Well Tolerated Across All Doses
Express News | Pliant Therapeutics Announces Interim Phase 1 Data Fro First Three Of Five Potential Cohorts Of Phase 1 Dose Escalation Trial Of PLN-101095; Says Antitumor Activity Observed With Confirmed Partial Responses In 50% Of Patients